一种针对被错误覆盖的蛋白质的新疗法显示,有希望减缓小鼠的运动神经元疾病。 A new therapy targeting misfolded proteins shows promise in slowing motor neurone disease in mice.

由Christen Chisholm博士率领的Wolloongong大学的一个团队开发了一种有希望的新疗法,用于使用名为Misform UbL的分子来治疗运动神经病(MND)的遗传形式。 A team at the University of Wollongong, led by Dr. Christen Chisholm, has developed a promising new therapy for a genetic form of motor neurone disease (MND) using a molecule called Misfold UbL. 治疗指标和标签被误叠的SOD1蛋白质(与MND有关)使人体的自然废物系统能够在形成有害垃圾堆之前销毁这些蛋白质。 The treatment targets and tags misfolded SOD1 proteins—linked to MND—enabling the body’s natural waste system to destroy them before they form harmful clumps. 在老鼠模型中,治疗减缓了症状发作、保护了运动神经元和保留了肌肉连接。 In mouse models, the therapy slowed symptom onset, protected motor neurons, and preserved muscle connections. 这项研究受已故Justin Yerbury博士作品的启发,并得到Fight MND的支持,为早期诊断提供了潜力,并可以应用于阿尔茨海默氏病和帕金森氏病等其他神经退化性疾病。 The research, inspired by the late Dr. Justin Yerbury’s work and supported by Fight MND, offers potential for earlier diagnosis and could apply to other neurodegenerative diseases like Alzheimer’s and Parkinson’s.